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Female adipose tissue-specific 
Bscl2 knockout mice develop only 
moderate metabolic dysfunction 
when housed at thermoneutrality 
and fed a high-fat diet
George D. Mcilroy  1, Sharon E. Mitchell2, Weiping Han3, Mirela Delibegović4 & 
Justin J. Rochford  1
Mutations affecting the BSCL2 gene cause the most severe form of congenital generalised 
lipodystrophy. Affected individuals almost completely lack adipose tissue and suffer from severe 
diabetes and metabolic complications. Likewise, mice lacking Bscl2 in all tissues have dramatically 
reduced adipose mass, glucose intolerance and hyperinsulinaemia. However, male adipose tissue-
specific Bscl2 knockout mice fail to develop the metabolic dysfunction observed in Bscl2 null mice and 
BSCL2 deficient patients, despite a similar generalised lack of adipose tissues. Clinical reports indicate 
gender differences frequently exist in cases of lipodystrophy, with female patients more adversely 
affected than male patients. We therefore generated and characterised female mice lacking Bscl2 
specifically in adipose tissue (Ad-B2(−/−)). We show that female Ad-B2(−/−) mice also develop early-onset 
lipodystrophy when fed a chow diet and are maintained under standard housing conditions (21 °C) 
or thermoneutrality (30 °C). Despite this, female Ad-B2(−/−) mice fail to develop severe metabolic 
dysfunction. Only when female Ad-B2(−/−) mice are maintained at thermoneutrality and fed a high-
fat diet do subtle alterations to metabolic homeostasis manifest. This is despite a striking inability to 
expand adipose mass. Our findings provide further evidence that loss of Bscl2 in non-adipose tissues 
may contribute to the severity of metabolic dysfunction in this condition.
Lipodystrophy is a term that is used to describe conditions featuring altered adipose tissue mass or distribu-
tion1. Under normal circumstances, adipose tissue depots are diverse and display a number of distinct functions, 
depending on their anatomical location2. However, the primary function of adipose tissue is to act as a storage 
site, safely sequestering excessive energy intake in the form of triglyceride and releasing this in times of metabolic 
need. In conditions of lipodystrophy, this storage capacity is severely impaired as a result of abnormal adipose 
tissue development and/or maintenance1. This leads to the inappropriate accumulation of lipids into non-adipose 
tissues, which are not specifically adapted for this purpose. Consequently, patients suffering from either genetic 
or acquired forms of lipodystrophy manifest abnormalities in metabolic homeostasis, such as hepatic steatosis, 
hypertriglyceridemia and insulin resistance3. The severity of metabolic dysfunction that presents in patients with 
lipodystrophy can vary due to the extent and site of adipose tissue loss as well as gender1.
Congenital generalized lipodystrophy (CGL) is characterised by the near complete lack of adipose tissue, 
which leads to the development of severe metabolic dysfunction4. CGL is a rare genetic disorder that is inherited 
in an autosomal recessive manner. Four subtypes of CGL have been identified, which result from mutations 
in AGPAT2 (CGL1)5, BSCL2 (CGL2)6, CAV1 (CGL3)7 and PTRF (CGL4)8. Of the four types, the most severe 
form of CGL observed in humans is caused by mutations that affect the BSCL2 gene (CGL2). BSCL2 encodes 
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a trans-membrane protein called seipin that is located in the endoplasmic reticulum9,10. In vitro studies have 
revealed that seipin is critical for the development of adipocytes, as knockdown of Bscl2 in pre-adipocyte cell lines 
leads to the inhibition of adipogenesis11,12. Seipin has also been shown to be capable of forming homo-oligomeric 
structures13,14. These appear to act as molecular scaffolds, capable of binding important regulators of triacylglyc-
erol and glycerophospholipid synthesis such as LIPIN1, AGPAT2 and GPAT315–17.
The generation of in vivo models to investigate CGL2 has also provided further insights and understanding of 
this severe genetic disorder. To date, four independent groups have generated global Bscl2 knockout mouse mod-
els18–21. All four animal models are lipodystrophic and develop severe hepatic steatosis, glucose intolerance and 
insulin resistance. Therefore Bscl2 null mice almost entirely recapitulate the metabolic disturbances observed in 
the human condition22. Tissue-specific knockout models have also been generated to try and further understand 
and characterise this condition23–25. We recently reported that adipose tissue-specific ablation of Bscl2 from birth 
is sufficient to cause early-onset generalised lipodystrophy in male mice21. Surprisingly however, this model failed 
to develop the severe metabolic dysfunction that is observed in global Bscl2 knockout mice, even when challenged 
with a high-fat diet. Interestingly, it is reported that women are typically more severely affected by lipodystrophy1. 
Indeed, clinical evidence suggests gender differences in genetic forms of lipodystrophy such as CGL2 or familial 
partial lipodystrophy (Dunnigan type)26,27, where female patients are more affected by metabolic complications 
than male patients. For this reason, we investigated whether female mice that lack seipin specifically in adipose 
tissue would develop metabolic dysfunction, despite this not being apparent in our previous study of male mice21. 
In addition, significant preservation of brown adipose mass has been observed in all Bscl2 null mouse models, as 
well as in our adipose specific Bscl2 knockout mice18–21. Therefore, we also examined whether the thermogenic 
activity of this tissue might protect mice from the metabolic consequences of lipodystrophy due to adipose spe-
cific Bscl2 ablation.
In this study, we have generated and characterised female mice that lack Bscl2 specifically in developing and 
mature adipocytes using the Adipoq-Cre model. Our data reveal that loss of seipin specifically in adipose tissue of 
female mice is sufficient to cause generalised lipodystrophy early in life. However, severe metabolic dysfunction is 
not apparent in chow fed mice when maintained under standard housing temperatures (21 °C) or when placed at 
thermoneutral housing conditions (30 °C). Signs of metabolic dysfunction only begin to manifest in aged female 
mice lacking Bscl2 specifically in adipose tissue, after being challenged with a high-fat diet when housed under 
thermoneutral conditions. This is despite an inability to expand adipose mass which is apparent in control mice 
under these conditions. These findings provide further evidence that ablation of Bscl2 in adipose tissue alone 
appears to be insufficient to recapitulate the full metabolic phenotype observed in global Bscl2 knockout mice 
and patients that suffer from CGL2.
Results
Adipose tissue-specific deletion of Bscl2 is sufficient to cause lipodystrophy in female mice. 
Female mice lacking Bscl2 specifically in developing and mature adipocytes (Ad-B2(−/−) mice) were generated 
by crossing Bscl2 flox’d mice (B2(fl/fl)) with heterozygous Bscl2 flox’d mice (B2(fl/+)) also carrying Cre recombinase 
driven by the Adipoq promoter, as previously described21. The specificity of Bscl2 ablation was confirmed by 
qPCR. Bscl2 mRNA transcript levels were significantly decreased by ~40% in Ad-B2(+/−) and ~95% in Ad-B2(−/−) 
female mice compared to B2(fl/fl) female mice in both gonadal white adipose tissue (GWAT) and brown adipose 
tissue (BAT). However, no significant differences in Bscl2 gene expression levels were detected in the liver, heart 
or kidney between any of the genotypes (Fig. 1A). Similarly to findings observed in male Ad-B2(−/−) mice21, no 
significant differences in body weight were detected between any genotype when female mice were fed a standard 
rodent chow diet and maintained under standard housing temperature (21 °C) conditions (Fig. 1B). Echo-MRI 
analysis revealed that female Ad-B2(−/−) mice had significantly decreased fat mass levels (Fig. 1C) and significantly 
increased lean mass levels (Fig. 1D) as a percentage of bodyweight compared to both B2(fl/fl) and Ad-B2(+/−) mice 
at six weeks of age. Significant changes in fat mass and lean mass as a percentage of body weight were also observed 
at twelve weeks of age, but this was only apparent between B2(fl/fl) and Ad-B2(−/−) female mice (Fig. 1C,D). 
Absolute lean mass was not found to be significantly different at six weeks of age, however female Ad-B2(−/−) 
mice had significantly increased lean mass compared to Ad-B2(+/−) mice at twelve weeks of age (Fig. S1A). 
Gene expression analysis of GWAT in sixteen week old female mice revealed significant decreases in Adipoq in 
Ad-B2(−/−) mice compared to B2(fl/fl) and Ad-B2(+/−) mice and decreases in Leptin were found in Ad-B2(−/−) mice 
compared to B2(fl/fl) controls (Fig. 1E). Circulating serum levels of adiponectin and leptin in mice fasted for five 
hours showed similar alterations to those seen at the mRNA transcript level (Fig. 1F,G). The findings presented 
therefore indicate that similarly to that observed in male Ad-B2(−/−) mice21, ablation of Bscl2 specifically in devel-
oping and mature adipocytes in female mice is sufficient to cause lipodystrophy.
Female Ad-B2(−/−) mice do not develop severe metabolic dysfunction. Global Bscl2 knockout 
mouse models are lipodystrophic and develop severe metabolic dysfunction, similarly to patients with pathogenic 
mutations in BSCL218–21. We recently reported that adipose tissue-specific ablation of Bscl2 in male mice is suffi-
cient to cause lipodystrophy, yet severe metabolic dysfunction does not manifest in this model21. To determine if 
this was also the case in Ad-B2(−/−) female mice, we performed glucose tolerance tests at ten weeks of age in chow 
fed mice maintained under standard housing temperatures (21 °C). In mice fasted for five hours, basal blood 
glucose levels were not found to be significantly different between genotypes (Fig. 2A). Although Ad-B2(−/−) 
female mice appeared to exhibit a slight impairment in the ability to clear a glucose bolus during the glucose 
tolerance test compared to B2(fl/fl) and Ad-B2(+/−) controls (Fig. 2B), this failed to reach statistical significance at 
any time point. When serum parameters were examined at sixteen weeks of age in mice fasted for a period of five 
hours, no significant differences in circulating insulin, glucose or triglyceride levels were observed (Fig. S1B–D). 
Quantitative insulin sensitivity check index (QUICKI) analysis also indicated that female Ad-B2(−/−) mice were 
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not insulin resistant compared to control animals (Fig. S1E). Additionally, no significant differences were detect-
able in liver triglyceride levels between any of the genotypes (Fig. S1F). When interscapular BAT mass was exam-
ined however, female Ad-B2(−/−) mice had significantly decreased amounts of this adipose tissue depot (~60%) 
compared to B2(fl/fl) and Ad-B2(+/−) mice (Fig. 2C). The extent of BAT loss in this model was more severe than that 
previously observed in male Ad-B2(−/−) mice where BAT mass was reduced by only ~19% compared to Ad-B2(+/−) 
mice21. We next examined if ablation of Bscl2 in BAT caused any alterations to gene expression levels of white and 
brown adipose tissue markers. Significant decreases in Pparγ, C/ebpα, Plin, aP2, Adipoq, Cpt1β and Pparα were 
observed in BAT from Ad-B2(−/−) mice compared to both B2(fl/fl) and Ad-B2(+/−) female mice (Fig. 2D). Transcript 
levels of Leptin, Ucp1, Pgc1α, and Prdm16 also showed a similar trend to be decreased in Ad-B2(−/−) mice, but 
were not found to be significantly different. Both global Bscl2 knockout mice and male Ad-B2(−/−) mice have been 
shown to display elevated gene expression levels of thermogenic markers in residual epididymal white adipose 
tissue (EWAT) depots19,21. To determine if this was also true in female mice, markers of white and brown adipose 
tissue were examined in the GWAT depot. Levels of Plin and aP2 were significantly decreased in Ad-B2(−/−) 
mice but only compared to B2(fl/fl) controls, however no significant changes were found between any genotype 
for Pparγ, C/ebpα or Glut4 (Fig. 2E). Unlike the increased expression of markers of thermogenesis such a Ucp1, 
Cpt1β or Pgc1α in EWAT observed in male Ad-B2(−/−) mice21, we saw no significant increases in the expression 
of these genes in the GWAT of Ad-B2(−/−) female mice (Fig. 2E). The data reveal that, similarly to male Ad-B2(−/−) 
mice, adipose tissue specific ablation of Bscl2 in female mice is insufficient to cause severe metabolic dysfunction. 
However, gender differences are apparent as BAT appears to be more affected by Bscl2 loss than in male mice, and 
female mice do not display increases in markers of thermogenesis in residual GWAT depots.
Housing female Ad-B2(−/−) mice at thermoneutrality does not impair glucose tolerance. Mice 
that are maintained at standard housing temperatures (21 °C) are under a constant thermal stress. They are able 
Figure 1. Adipose specific ablation of Bscl2 in female mice is sufficient to cause lipodystrophy. (A) Bscl2 mRNA 
levels of sixteen week old B2(fl/fl), Ad-B2(+/−) and Ad-B2(−/−) mice at standard housing temperatures (21 °C) 
in GWAT, BAT, liver, heart and kidney (n = 3–4). (B) Body weight progression of B2(fl/fl), Ad-B2(+/−) and Ad-
B2(−/−) mice (n = 4–8). Fat mass (C) and lean mass (D) levels assessed by Echo-MRI and normalised to body 
weight in B2(fl/fl), Ad-B2(+/−) and Ad-B2(−/−) mice at six and twelve weeks of age (n = 4–8). Relative GWAT 
mRNA levels (E) and circulating serum levels of adiponectin (F) and leptin (G) in sixteen week old B2(fl/fl), Ad-
B2(+/−) and Ad-B2(−/−) mice fasted for five hours (n = 4). All data are presented as the mean ± SEM, *p < 0.05 vs 
B2(fl/fl), #p < 0.05 vs Ad-B2(+/−).
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to maintain their core body temperature by increasing rates of energy metabolism through adaptive thermo-
genesis28. In order to determine if the residual BAT in Ad-B2(−/−) female mice was offering any protection from 
developing glucose intolerance, we placed a separate cohort of eleven week old B2(fl/fl), Ad-B2(+/−) and Ad-B2(−/−) 
female mice at thermoneutral housing conditions (30 °C) for a period of nine weeks. Once again, we found no 
significant differences in body weight between any of the genotypes, both prior to and throughout the nine week 
housing period at thermoneutrality (Fig. 3A). After eight weeks of housing at thermoneutrality, dual-energy 
X-ray absorptiometry (DEXA) analysis was performed. The findings revealed that Ad-B2(−/−) female mice had 
significantly decreased fat mass levels (Fig. 3B) and significantly increased lean mass levels (Fig. 3C) as a per-
centage of body weight compared to both B2(fl/fl) and Ad-B2(+/−) controls. Absolute lean mass was also signif-
icantly increased in Ad-B2(−/−) female mice compared to Ad-B2(+/−) mice (Fig. S1G). Thus, Ad-B2(−/−) female 
mice are similarly lipodystrophic when housed under thermoneutral temperature conditions. After nine weeks 
at thermoneutrality, five hour fasted basal blood glucose levels were again found to not be significantly different 
(Fig. 3D) and glucose tolerance tests once again indicated that Ad-B2(−/−) female mice were not glucose intolerant 
compared controls (Fig. 3E). Overall, the data presented reveal that lipodystrophic female Ad-B2(−/−) mice fed a 
standard rodent chow diet that are housed under thermoneutral conditions fail to develop glucose intolerance. 
This is in stark contrast to global Bscl2 knockout mouse models that develop severe metabolic dysfunction when 
fed a standard chow diet and are kept under standard housing temperatures.
High-fat diet fed Ad-B2(−/−) female mice housed at thermoneutrality resist diet induced weight 
gain. As glucose tolerance did not worsen by housing female Ad-B2(−/−) mice at thermoneutrality, we next 
challenged them by feeding them a high-fat diet (HFD, 60% kcal from fat) for four weeks. Similarly to male 
Ad-B2(−/−) mice fed a HFD at standard housing temperatures21, Ad-B2(−/−) female mice resisted diet induced 
weight gain compared to B2(fl/fl) and Ad-B2(+/−) controls (Fig. 4A). This was even more apparent when repre-
sented as a percentage of body weight gain, as Ad-B2(−/−) mice were significantly different compared to both 
B2(fl/fl) and Ad-B2(+/−) mice at two, three and four weeks of HFD feeding (Fig. 4B). Once again, gene expression 
Figure 2. Metabolic consequences of adipose tissue-specific Bscl2 deletion in female mice. Five hour fasted 
blood glucose levels (A) and glucose tolerance test (B) in B2(fl/fl), Ad-B2(+/−) and Ad-B2(−/−) mice at ten weeks 
of age (n = 4). (C) BAT weight normalised to body weight in sixteen week old mice (n = 3–4). mRNA levels of 
white and brown markers in (D) BAT (n = 3–4) and (E) GWAT (n = 4) in sixteen week old mice. All data are 
presented as the mean ± SEM, *p < 0.05 vs B2(fl/fl), #p < 0.05 vs Ad-B2(+/−).
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analysis of GWAT in twenty-eight week old female mice revealed significant decreases in Adipoq and Leptin in 
Ad-B2(−/−) mice compared to both B2(fl/fl) and Ad-B2(+/−) female mice (Fig. 4C). Additionally, circulating serum 
levels of adiponectin and leptin in mice fasted for five hours showed similar significant alterations to those seen 
at the mRNA transcript level (Fig. 4D,E). This indicates that Ad-B2(−/−) mice continue to display severe disrup-
tion to adipose tissue development even when fed a HFD at thermoneutral conditions. When interscapular BAT 
mass was examined, the weight of this adipose depot had increased from ~2 mg/g, seen at standard housing 
temperatures, to ~3 mg/g at thermoneutrality in both B2(fl/fl) and Ad-B2(+/−) female mice. This is consistent with 
enhanced lipid accumulation in this anatomical BAT depot and accumulation of WAT-like cells. BAT mass in 
female Ad-B2(−/−) mice had also increased to levels that were now not significantly different to control animals 
(Fig. S1H). Examination of white adipose tissue markers in BAT revealed that, C/ebpα, Plin, aP2, Adipoq and 
Leptin were not as dramatically impaired in Ad-B2(−/−) mice when compared with the differences observed under 
standard housing temperatures. This was despite the almost complete ablation of Bscl2 (Fig. 4F). Brown adipose 
tissue markers such as Ucp1, Cpt1β, Pgc1α, Prdm16 and Pparα however were similarly impaired or even more 
affected (Fig. 4F) than previously observed under standard housing temperatures. Gene expression analysis in 
GWAT revealed only small decreases to Pparγ and Glut4 in Ad-B2(−/−) mice but no significant differences were 
observed in the expression of C/ebpα, Plin, aP2 or Pgc1α. Interestingly, however, significant increases in Ucp1 and 
Cpt1β were now seen in Ad-B2(−/−) female mice compared to both B2(fl/fl) and Ad-B2(+/−) control mice (Fig. 4G).
Figure 3. Female Ad-B2(−/−) mice housed at thermoneutrality are not glucose intolerant. (A) Body weight 
progression of B2(fl/fl), Ad-B2(+/−) and Ad-B2(−/−) mice place at thermoneutrality (30 °C) at eleven weeks of age 
(n = 5–6). Fat mass (B) and lean mass (C) levels assessed by DEXA normalised to body weight in B2(fl/fl),  
Ad-B2(+/−) and Ad-B2(−/−) mice after eight weeks at thermoneutrality (n = 5–6). Five hour fasted blood 
glucose levels (D) and glucose tolerance test (E) in B2(fl/fl), Ad-B2(+/−) and Ad-B2(−/−) mice after nine weeks at 
thermoneutrality (n = 5–6). All data are presented as the mean ± SEM, *p < 0.05 vs B2(fl/fl), #p < 0.05 vs Ad-
B2(+/−).
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High-fat diet fed Ad-B2(−/−) female mice housed at thermoneutrality only partially develop 
metabolic dysfunction. We next determined if feeding Ad-B2(−/−) female mice a HFD when housed under 
thermoneutral conditions had had any impact on metabolic health. After four weeks of HFD feeding under ther-
moneutral conditions, five hour fasted basal blood glucose levels were found to be significantly elevated, but only 
when compared to Ad-B2(+/−) control mice (Fig. 5A). When glucose tolerance tests were performed, Ad-B2(−/−) 
female mice had significantly elevated blood glucose levels at 15 minutes after being injected with a glucose bolus, 
however this was only apparent compared to Ad-B2(+/−) mice (Fig. 5B). No significant differences however were 
found between any of the genotypes at 30, 60 or 120 minutes post glucose injection. We next examined serum 
parameters in twenty-eight week old mice that had been fasted for five hours. Circulating insulin levels showed a 
trend to be elevated in Ad-B2(−/−) female mice, however this failed to reach statistical significance against control 
female mice (Fig. 5C). Serum glucose levels were again found to be significantly increased in Ad-B2(−/−) mice, 
but only when compared to Ad-B2(+/−) controls (Fig. 5D). Serum triglyceride levels continued not to be signifi-
cantly different between any of the genotypes under these conditions (Fig. 5E). QUICKI analysis indicated that 
Ad-B2(−/−) female mice had significantly lower values compared to Ad-B2(+/−) female mice but not B2(fl/fl) female 
mice (Fig. 5F). This indicates that female Ad-B2(−/−) mice appear to have developed modest insulin resistance, 
at least when compared to Ad-B2(+/−) controls. Interestingly, when lipid levels were examined in the livers of 
these animals, Ad-B2(−/−) female mice had significantly elevated triglyceride levels compared to both B2(fl/fl) and 
Ad-B2(+/−) control mice (Fig. 5G). This provides further evidence to suggest that Ad-B2(−/−) female mice are una-
ble to safely store dietary lipids in adipocytes as a consequence of lipodystrophy caused by the ablation of Bscl2 
specifically in adipose tissue. Overall, these findings show that adipose specific ablation of seipin in Ad-B2(−/−) 
female mice causes lipodystrophy, but does not cause the overt metabolic disease observed with congenital loss of 
seipin in mice or humans. This is similar to our previous findings in male mice. However, here Ad-B2(−/−) female 
mice were also simultaneously subjected to HFD feeding and thermoneutral housing. Despite a striking inability 
to expand their adipose mass under these metabolically challenging conditions, they only developed mild dys-
regulation of glucose metabolism.
Figure 4. High-fat diet fed female Ad-B2(−/−) mice resist weight gain at thermoneutrality. Body weight 
progression (A) and percentage of body weight gain (B) in twenty-four week old B2(fl/fl), Ad-B2(+/−) and Ad-
B2(−/−) female mice housed at thermoneutrality and fed a high-fat diet for four weeks (n = 5–6). Relative GWAT 
mRNA levels (C) and circulating serum levels of adiponectin (D) and leptin (E) in twenty-eight week old B2(fl/
fl), Ad-B2(+/−) and Ad-B2(−/−) mice fasted for 5 hours (n = 5–6). mRNA levels of white and brown markers in (F) 
BAT (n = 4–6) and (G) GWAT (n = 5–6) in twenty-eight week old B2(fl/fl), Ad-B2(+/−) and Ad-B2(−/−) mice. All 
data are presented as the mean ± SEM, *p < 0.05 vs B2(fl/fl), #p < 0.05 vs Ad-B2(+/−).
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Discussion
Pathogenic mutations that affect the BSCL2 gene cause the most severe form of congenital generalised lipod-
ystrophy known in humans6. Patients with this condition suffer from an almost complete lack of adipose tissue 
and develop metabolic complications such as hepatic steatosis, hypertriglyceridemia and insulin resistance29. We 
recently reported that adipose tissue-specific ablation of Bscl2 is sufficient to cause early-onset generalised lipod-
ystrophy in male mice21. Surprisingly however, this mouse model failed to develop the severe metabolic dysfunc-
tion observed in global Bscl2 knockout mice18–21. Interestingly, clinical reports suggest that sexual dimorphism 
may exist in conditions of lipodystrophy, as female patients appear to be more severely affected by metabolic com-
plications than male patients, although this has not been examined systematically or experimentally26,27. For this 
reason, we examined whether adipose tissue-specific loss of Bscl2 in female mice would lead to the development 
of metabolic dysfunction which had not been apparent in male mice.
Here we show that female Ad-B2(−/−) mice fed a chow diet and maintained at standard housing temperatures 
(21 °C) develop lipodystrophy as young as six weeks of age, with significantly decreased levels of adiposity and 
increased lean mass levels. Consistent with alterations in adipose tissue development, significant decreases in 
mRNA transcripts and circulating serum levels of the adipokines adiponectin and leptin were also apparent. 
Despite this, female Ad-B2(−/−) mice failed to develop severe metabolic dysfunction under these conditions, simi-
lar to the situation we have previously described in male Ad-B2(−/−) mice21. Although there were no major differ-
ences between genders in terms of metabolic dysfunction, BAT mass was more significantly reduced in females 
than we had previously found in male mice21. In addition, female mice did not display increased expression of 
markers of thermogenesis in residual GWAT depots, which were evident in EWAT of both global and adipose 
tissue-specific knockout male mice19,21,25. BAT is capable of significant energy dissipation via heat generation due 
Figure 5. Female Ad-B2(−/−) mice only develop moderate metabolic dysfunction when fed a high-fat diet 
at thermoneutrality. Five hour fasted blood glucose levels (A) and glucose tolerance test (B) at twenty-eight 
weeks of age in B2(fl/fl), Ad-B2(+/−) and Ad-B2(−/−) mice housed at thermoneutrality and fed a high-fat diet 
for four weeks (n = 5–6). Five hour fasted circulating serum levels of insulin (C), glucose (D), triglyceride 
(E) and quantitative sensitivity check index analysis (F) in twenty-eight week old B2(fl/fl), Ad-B2(+/−) and Ad-
B2(−/−) female mice housed at thermoneutrality and fed a high-fat diet for four weeks (n = 5–6). (G) Liver 
triglyceride levels normalised to tissue weight in five hour fasted B2(fl/fl), Ad-B2(+/−) and Ad-B2(−/−) mice housed 
at thermoneutrality and fed a high-fat diet for four weeks (n = 5–6). All data are presented as the mean ± SEM, 
*p < 0.05 vs B2(fl/fl), #p < 0.05 vs Ad-B2(+/−).
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to adaptive thermogenesis30–32. Moreover, activation of BAT thermogenesis can improve glucose tolerance both 
in mice and humans33,34. Hence, the greater severity of BAT loss in female Ad-B2(−/−) mice could explain why 
we find that female mice display modestly dysregulated glycaemic control, which was not apparent in their male 
counterparts21. However, these changes were subtle and glucose tolerance tests in female mice were not signifi-
cantly altered whilst other parameters of metabolic dysfunction were not changed.
Although significant alterations to BAT mass are apparent in both global and adipose tissue-specific Bscl2 
knockout mice18–21, previous studies indicate that loss of Bscl2 does not impair the brown adipogenic differenti-
ation program per se35,36. Indeed, Bscl2 knockout mice are capable of maintaining their core body temperature 
when acclimatised to cold temperatures (4 °C) and fed ad libitum, indicating that Bscl2 deficiency is likely to play 
a non-cell autonomous role in the decreased BAT mass observed in these models36. As our female Ad-B2(−/−) 
mice were initially maintained under standard housing temperatures (21 °C), they may be considered to be under 
chronic thermal stress and effectively increase their metabolic rate in order to defend their body temperature. We 
therefore examined female Ad-B2(−/−) mice under thermoneutral conditions (30 °C), which can uncover meta-
bolic phenotypes by reducing lipid and carbohydrate oxidation linked to thermogenesis28. Female Ad-B2(−/−) 
mice did not show any differences in body weight, were lipodystrophic and remained glucose tolerant despite 
being housed at thermoneutrality for nine weeks. Thus, lipodystrophy as a consequence of adipose-specific Bscl2 
ablation remained insufficient to cause the severe metabolic dysfunction that is observed in global Bscl2 knock-
out mouse models18–21. To challenge this cohort further, we fed mice a HFD for a period of four weeks. Just as 
observed in male Ad-B2(−/−) mice21, female Ad-B2(−/−) mice resisted high-fat diet induced weight gain due to a 
failure of adipose tissue expansion. Whilst severe metabolic dysfunction was still not apparent under these con-
ditions, female Ad-B2(−/−) mice did show modest changes, indicative of metabolic complications. Therefore, it is 
possible to induce symptoms of metabolic dysfunction in Ad-B2(−/−) female mice compared to controls, however, 
these only become apparent when mice are simultaneously aged under thermoneutral conditions and challenged 
with a HFD.
BSCL2 is widely expressed throughout the body6, yet it is a commonly held view that all the metabolic conse-
quences of CGL2 can be explained solely by the lack of adipose tissue development. There is evidence to support 
this, as re-establishing Bscl2 selectively in adipose tissue of Bscl2 null mice is capable of restoring significant adi-
pose mass as well as preventing insulin resistance and severe hepatic steatosis37. However, this does not exclude 
the possibility that when adipose tissue is lacking in CGL2, the additional loss of seipin in non-adipose tissues 
impairs their ability to compensate for this, increasing the severity of metabolic dysfunction. Experiments exam-
ining the specific ablation of Bscl2 in the liver have also revealed that this alone does not lead to the development 
of a metabolic phenotype, even when mice were fed a HFD24. This also appears to support the notion that the loss 
of adipose tissue is exclusively responsible for metabolic disease in CGL2. However, liver-specific Bscl2 knockout 
mice have normal adipose tissue development and functional adipose mass. It is therefore credible that this could 
protect them from developing metabolic dysfunction.
It is interesting to note that the onset of metabolic complications in our model coincides with significantly 
elevated liver triglyceride levels in female Ad-B2(−/−) mice compared to control animals. Severe hepatic steatosis 
is a striking feature found in all Bscl2 global knockout mice18–21 and in patients that suffer from CGL24. Due to 
the use of the Adipoq-Cre driver to ablate Bscl2 specifically in adipose tissue, Bscl2 mRNA levels in the liver are 
unaffected in female Ad-B2(−/−) mice. Consequently, the presence of functional seipin within the liver of our 
model may offer some protection from the development of severe metabolic dysfunction. For example, in chow 
fed female Ad-B2(−/−) mice maintained under standard conditions, seipin’s acknowledged role in regulating lipid 
droplet dynamics may enable dietary lipids to be safely packaged or utilised within hepatocytes, although they 
would otherwise normally be stored in adipose tissue. However, when challenged sufficiently, e.g. with a HFD at 
30 °C, a threshold may be reached where this safe hepatic lipid storage is overwhelmed and metabolic dysfunc-
tion begins to develop. In contrast, global Bscl2 knockout mouse would lack this protective role of seipin within 
the liver, which could lead to more rapid and harmful lipid accumulation within hepatocytes, regardless of the 
housing or dietary conditions.
In support of this view, a recent report has highlighted that Bscl2 does appear to play a cell autonomous role 
within the liver. Knockdown of Bscl2 resulted in an increase in both the number and size of intracellular lipid 
droplets within hepatocytes38. Additional evidence is beginning to emerge that Bscl2 may have other cell auton-
omous roles in other non-adipose tissues, which could play important roles in metabolic homeostasis. Another 
recent study has found that global Bscl2 knockout mice exhibit impaired kidney function, with increased renal 
lipid deposition and elevations in glycosuria39. Adipose tissue transplant partially rescued renal function in Bscl2 
knockout mice, indicating that loss of adipose tissue was at least partly responsible for kidney disease in these 
mice. However, further studies will be needed in order to confirm whether the loss of Bscl2 specifically in the 
kidney also contributes. Previous studies have shown that the hypertrophic cardiomyopathy phenotype observed 
in Bscl2 null mice appears to be caused by hyperglycaemia, rather than the loss of Bscl2 in cardiac tissue40. Seipin 
is also abundantly expressed in some brain regions and neuronal populations associated with the regulation 
of energy balance including, the paraventricular nucleus of the hypothalamus and dorsal vagal complex in the 
brainstem6,41,42. However, the ability of seipin in specific neuronal populations to influence metabolic health has 
yet to be probed in detail. The use of alternative tissue-specific knockout mouse models will be needed to dissect 
the potential roles of seipin in the kidney, brain and other tissues in order to understand its potential importance 
in metabolic actions outside adipose tissue.
Overall, our findings along with recently published data indicate that Bscl2 may play important roles in 
non-adipose tissues that might contribute to the development of severe metabolic dysfunction in CGL2. If this 
is the case, these previously overlooked tissues could represent novel targets for therapeutic intervention. Indeed 
this approach is already exemplified by leptin replacement therapy in CGL, where insulin resistance and hepatic 
steatosis is ameliorated without altering adipose tissue mass43. Further efforts should therefore be made to fully 
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understand and characterise the mechanistic role played by seipin in non-adipose tissues. This information could 
provide new insights regarding how metabolic dysfunction develops in patients with congenital generalised lipo-
dystrophy, but also in individuals suffering from other forms of adipose tissue dysfunction such as in obesity.
Methods
Animal studies. Bscl2 flox’d mice (B2(fl/fl)) were generated as previously described21. To generate adipo-
cyte-specific seipin knockout mice (Ad-B2(−/−)), B2(fl/fl) mice were crossed with heterozygous B2(fl/+) mice also 
carrying Cre recombinase driven by the Adipoq promoter (Adiponectin-Cre). Adiponectin-Cre mice were gener-
ously provided by Dr Evan Rosen, Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, USA. 
Animal procedures were approved by the University of Aberdeen Ethics Review Board and performed under pro-
ject licenses (PPL: P94B395EO and PFAD33FA2) approved by the UK Home Office. All experiments used female 
mice, which were group-housed at standard housing temperatures (21 °C) and exposed to a 12 hr/12 hr light-dark 
period. For studies performed at thermoneutrality, eleven week old female mice were group-housed at 30 °C and 
exposed to a 12 hr/12 hr light-dark period. Female B2(fl/fl) mice and mice heterozygous for both Adiponectin-Cre 
and B2(fl/f) (Ad-B2(+/−)) that were littermates to Ad-B2(−/−) mice were used as controls. Mice were always given ad 
libitum access to water and a standard rodent chow diet (CRM (P) 801722, Special Diets Services) unless other-
wise stated. Tissues were rapidly dissected post-mortem, frozen in liquid nitrogen then stored at −70 °C.
Metabolic studies. Fat and lean mass normalised to body weight were measured in mice aged six and 
twelve weeks (standard housing temperatures) using the EchoMRI™-500 body composition analyser (Zinsser 
Analytic GmbH) or nineteen weeks of age (thermoneutrality) by dual-energy X-ray absorptiometry (DEXA, 
Lunar PIXImus). Prior to glucose tolerance tests (GTT), mice were placed into clean cages and food was withheld 
for five hours. Basal glucose readings (0 min) were determined by glucometer readings (AlphaTrak® II, Zoetisus) 
from tail punctures. Mice were then given a 2 mg/g d-glucose (Sigma) bolus by intraperitoneal injection. Blood 
glucose levels were monitored at 15, 30, 60 and 120 minutes. Mice had ad libitum access to water throughout. 
Twenty four-week-old Ad-B2(−/−), Ad-B2(+/−) and Bscl2(fl/fl) littermates housed at thermoneutrality were placed 
on a high-fat diet (60% kcals from fat (D12492), Research Diets) for four weeks. All mice had ad libitum access to 
food and water unless otherwise stated.
Gene expression. Total RNA was extracted from frozen tissues using the RNeasy mini kit (Qiagen) follow-
ing the manufactures protocol. Equal quantities of RNA were DNase I treated (Sigma) then reverse transcribed 
with M-MLV reverse transcriptase, 5X reaction buffer, dNTP’s and random primers (Promega). Real-time quan-
titative PCR was performed on the 7900HT system (Applied Biosystems) or CFX384 Touch™ Real-Time PCR 
Detection System (BioRad). NTC and NoRT controls were performed for every gene analysed. The geometric 
mean of three stable reference genes (Nono, Ywhaz and Hprt) was used for normalisation.
Serum analysis. Blood was collected from 16 week old chow fed mice (standard housing temperatures) or 
twenty eight week old HFD fed mice (thermoneutrality) fasted for five hours by cardiac puncture, placed and 
inverted in SST™ amber tubes (BD Microtainer®) and incubated at room temperature for 30 minutes. Samples were 
then centrifuged at 12,000 × g for 10 minutes and the separated serum collected. Insulin, Adiponectin and Leptin 
analysis was performed at the Core Biochemical Assay Laboratory (Cambridge, UK). Glucose levels were deter-
mined using the Glucose Colorimetric Assay Kit (Cayman Chemical) and following the manufacturer’s protocol 
provided. Serum triglyceride levels were determined using the Triglyceride Liquid Assay (Sentinel Diagnostics) fol-
lowing the manufacturer’s instructions. Quantitative insulin sensitivity check index (QUICKI) was calculated from 
fasting glucose (mg/dL) and insulin (µU/mL) values as previously described44. QUICKI = 1/[log(I0) + log(G0)], 
where I0 is fasting insulin and G0 is fasting glucose. QUICKI is a dimensionless index without units.
Liver TG assay. Frozen liver tissue samples were weighed and then homogenised in 1 ml of PBS. Samples were 
kept on ice at all times. Liver lysates were centrifuged at 12,000 × g for 10 minutes at 4 °C. The supernatant was 
collected and triglyceride (TG) levels were determined using the Triglyceride Liquid Assay (Sentinel Diagnostics) 
following the manufacturer’s instructions. TG levels were then normalised to individual tissue weights.
Statistical analyses. All data are presented as the mean ± SEM and were analysed by one-way analysis of 
variance with Tukey post-hoc test or two-way repeated measures analysis of variance with Bonferroni post-hoc 
test as appropriate using GraphPad Prism. A P-value < 0.05 was considered as statistically significant.
Data Availability Statement
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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